ClinicalTrials.gg
Enrolling by invitationNCT06995846Updated May 30, 2025

Application of Bacterial DNA Quantitative Detection in Diagnosis of SBP in Cirrhosis: A Multi Center Diagnostic Experiment

An observational study in Cirrhosis, Ascites and Bacterial Infections, sponsored by Beijing YouAn Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-30.

Primary conditionAscitesRegistry: FibrosisReclassifiedWhy we changed it
Registry
Fibrosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ascites
Why
  1. Fibrosis is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Ascites.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Beijing YouAn Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as enrolling by invitation.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Ages
18 Years and older
Sex
All
01

Study summary

Background and Significance:

Spontaneous bacterial peritonitis (SBP) is a common and life-threatening complication in patients with liver cirrhosis, characterized by high incidence and mortality. The current diagnostic standard relies on ascitic fluid polymorphonuclear leukocyte (PMN) count ≥250 cells/μL. However, this threshold is associated with high rates of missed diagnoses, poor correlation with clinical symptoms, and delays in pathogen identification due to the low sensitivity and prolonged time of traditional ascitic fluid culture.

With the development of molecular diagnostics, bacterial DNA (bactDNA) detection-especially through droplet digital PCR (ddPCR)-has emerged as a promising technique due to its high sensitivity, absolute quantification capability, and robustness. This study aims to evaluate the diagnostic value and accuracy of ddPCR-based quantification of bacterial DNA in ascitic fluid for SBP, providing a novel and objective diagnostic tool to improve early and accurate detection and to inform targeted antimicrobial therapy.

Objectives:

To assess the diagnostic accuracy (sensitivity, specificity, predictive values) of ddPCR-based quantification of total bacterial DNA in ascitic fluid for SBP.

To evaluate the diagnostic performance of the ratio of Gram-positive to Gram-negative bacterial DNA (G+/G-) in predicting SBP.

To explore the potential of ddPCR-based bacterial DNA quantification as a complementary or alternative method to conventional PMN-based diagnostic criteria.

Study Design and Methods:

This is a prospective diagnostic study involving 700 patients with liver cirrhosis and ascites. Ascitic fluid samples will be analyzed using ddPCR to quantify bacterial DNA levels. These results will be compared with traditional diagnostic criteria, including PMN counts and expert panel assessments based on clinical symptoms and laboratory findings. Statistical analyses will include correlation analysis, ROC curve analysis, and consistency testing.

Expected Outcomes:

The study aims to establish the clinical efficacy of ddPCR-based quantification of bacterial DNA in ascitic fluid as a novel diagnostic marker for SBP. This method is expected to be particularly useful in atypical cases where PMN counts are \<250/μL and may help guide preliminary antibiotic selection based on the proportion of Gram-positive and Gram-negative bacteria, thereby reducing empirical treatment failures and antibiotic resistance.

02

Conditions studied

  • Cirrhosis
  • Ascites
  • Bacterial Infections

Browse trials for

03

In context

Ascites Reclassified

247 studies on the registry are indexed under Ascites; 57 are open to participants now.

This study's planned enrollment of 700 is above the median of 100 across 54 observational studies indexed under Ascites.

Browse Ascites studies →

Lead sponsor

Beijing YouAn Hospital is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Compared within Ascites, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Cirrhotic ascites patients admitted to the liver disease departments of our hospital and various sub centers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years, no restriction on gender.
  • Diagnosis of liver cirrhosis based on imaging, biochemical, or hematological evidence of impaired hepatic synthetic function or portal hypertension, or confirmed cirrhosis, regardless of etiology.
  • Diagnosis of ascites according to the 2023 Chinese Clinical Guidelines for the Diagnosis and Treatment of Cirrhotic Ascites and Related Complications.

Exclusion criteria

Exclusion Criteria:

  • Patients with confirmed infections in other tissues or organs.
  • Ascites caused by non-hepatic etiologies, such as renal or cardiac ascites.
  • Pregnant individuals, intravenous drug users, or -infected individuals.
  • Patients with uncontrolled hepatocellular carcinoma or other systemic .
  • Patients who have previously undergone organ transplantation.
  • Patients currently receiving or other therapies.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cirrhotic Patients with Ascites

    Cirrhotic Patients with Ascites

    Diagnostic Test: Bacterial DNA Levels in Ascites

Interventions

  • Diagnostic testBacterial DNA Levels in Ascites

    The bactDNA was detected by droplet digital polymerase chain reaction (ddPCR).

06

What researchers measure

Primary outcomes

  1. spontaneous bacterial peritonitis (SBP)

    The SBP diagnosis is based on PMN (2021 practice Guidelines on the management of ascites in cirrhosis.) a clinical composite diagnosis (2023 Chinese guidelines)

    Time frame: From enrollment to the end of follow at 24 weeks

07

Study locations

1 site
  • No. 8 You An Men Wai Street, Fengtai District, Beijing 100069, China
    Beijing, China
08

References and documents

Individual participant data

Plan to share: Yes — all IPD collected throughout the trial

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06995846
Lead sponsor
Beijing YouAn Hospital
Responsible party
Zhongjie Hu (associate dean, Beijing YouAn Hospital) — Principal investigator
First posted
May 30, 2025
Start date
Apr 2, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
May 30, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion